Navigation Links
Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting

ctive anti-VEGF, VTA and VEA technologies. These positive developments in our clinical and preclinical programs reinforce our belief that the future for Peregrine has never been brighter, and we look forward to progressing these programs both on our own and with partners and collaborators going forward."

Highlights of seven of Peregrine's AACR presentations this week follow.

Peregrine's Selective Anti-VEGF Antibody Program

Drugs blocking vascular endothelial growth factor (VEGF) are proving very successful as anti-cancer agents, and for the first time researchers presented animal data on Peregrine's anti-VEGF antibodies that selectively block binding to the second of the two VEGF receptors. Current anti-VEGF drugs such as Avastin(R) block binding to both receptors, yet in preclinical studies comparing Peregrine's selective anti-VEGF antibody to Avastin, the selective antibodies compared favorably on all efficacy parameters assessed, inhibiting tumor growth by 90% in preclinical cancer models. Antibodies with greater selectivity may have advantages in clinical use since they have the potential to only inhibit angiogenesis while not impairing other functions of VEGF. Additional data that was presented showing the efficacy of Peregrine's fully human selective anti-VEGF antibody (R3) is expected to help facilitate the progress of this program towards clinical trials.

Broad Applicability and Versatility of Bavituximab, Peregrine's Targeted Anti-PS Antibody

Researchers affiliated with Peregrine presented a number of preclinical studies demonstrating the versatility and broad anti-cancer utility of bavituximab in major cancer models. They also reported data validating bavituximab's unique mechanism of action and supporting potential new applications of Peregrine's anti-PS technology platform. These included:

    *  Data supporting the potential use of bavituximab to enhance immune

       responses to existing tumors and as a po
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
2. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
3. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
4. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
5. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
11. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:9/29/2014)... N.C. , Sept. 29, 2014   ... one of the "Best Places to Work in ... a national leader in the sales and support ... Record solutions for physicians.  TSI Healthcare has over ... the country. The program, sponsored by ...
(Date:9/29/2014)... 2014 Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a ... diseases and cholesterol gallstones, announced today that it ... Medical Ltd. (TASE: ITMR) ("Itamar Medical"), a publicly-traded ... by the U.S. Food and Drug Administration, or ...
(Date:9/29/2014)... 29, 2014 On Friday, September ... 1.02%, the Dow Jones Industrial Average finished the day ... at 1,982.85, up 0.86%. The gains were broad based ... positive. The S&P 500 Health Care Sector Index ended ... has advanced 1.10% in the last one month. Investor-Edge ...
Breaking Medicine Technology:TSI Healthcare Named One of Modern Healthcare's "Best Places to Work in Healthcare" for Third Consecutive Year 2Galmed Pharmaceuticals and Itamar Medical to Collaborate on Assessing Aramchol's Effect on Endothelial Function 2Galmed Pharmaceuticals and Itamar Medical to Collaborate on Assessing Aramchol's Effect on Endothelial Function 3Pharma Equities Technical Momentum - Provectus Biopharma, Shire, Impax Labs, Zogenix, and TherapeuticsMD 2Pharma Equities Technical Momentum - Provectus Biopharma, Shire, Impax Labs, Zogenix, and TherapeuticsMD 3Pharma Equities Technical Momentum - Provectus Biopharma, Shire, Impax Labs, Zogenix, and TherapeuticsMD 4Pharma Equities Technical Momentum - Provectus Biopharma, Shire, Impax Labs, Zogenix, and TherapeuticsMD 5
... 6, 2011 Endologix, Inc. (Nasdaq: ELGX ... announced today that John McDermott, President and Chief Executive ... of America Merrill Lynch Health Care Conference in Las ... ConferenceDate:Tuesday, May 10, 2011Time:3:40 p.m. PTAn audio Web cast ...
... N.M., May 6, 2011 Qforma, the leading provider of ... health sciences industry, announced today the appointment of Mark Spiers ... President and CEO of Wolters Kluwer Pharma Solutions. ... leader in the pharmaceutical industry, to our Board," said Kelly ...
Cached Medicine Technology:Qforma Appoints New Member to Board of Directors 2
(Date:9/29/2014)... September 30, 2014 NAPW ... Professional, as a 2014 Professional Woman of the ... for leadership in medical device consulting. As the largest, ... spanning virtually every industry and profession, the National Association ... with over 600,000 members and nearly 300 Local Chapters. ...
(Date:9/29/2014)... 30, 2014 NAPW honors ... at Heaven Sent Consultation , as a 2014 ... with this prestigious distinction for leadership in marriage and ... professional women in the country, spanning virtually every industry ... a powerfully vibrant networking community with over 600,000 members ...
(Date:9/29/2014)... NAPW honors Natalie W. ... Private Pediatrics of Palm Beach as a 2014 ... leadership in pediatrics and family care with this prestigious ... the country, spanning virtually every industry and profession, the ... vibrant networking community with over 600,000 members and nearly ...
(Date:9/29/2014)... Park Avenue Dental, a leading ... A. Sherman who has dedicated his career to providing ... announced its inclusion in the Patient Connect 365 dentist ... to private accounts so that they may manage online ... system also allows patients to request appointments, better communicate ...
(Date:9/29/2014)... Denham Springs, LA (PRWEB) September 29, 2014 ... states their mission is to provide students with ... skills and awareness necessary to enhance their own ... Alliance of Fitness Professionals also benefits the community ... research, and service focused on the professional practice ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Announces Sandra Lee Bennett, Independent Medical Device Professional, a 2014 Professional Woman of the Year 2Health News:National Association of Professional Women Announces Carmel T. Ross, Marriage and Family Therapist at Heaven Sent Consultation, a 2014 Professional Woman of the Year 2Health News:National Association of Professional Women Announces Dr. Natalie W. Geary, Owner / President of Private Pediatrics of Palm Beach, a 2014 Professional Woman of the Year 2Health News:Florida’s Park Avenue Dental Now Part of Intuitive Patient Connect 365 Dentist Search Portal 2Health News:Florida’s Park Avenue Dental Now Part of Intuitive Patient Connect 365 Dentist Search Portal 3Health News:Narconon Louisiana New Life Retreat Announces Stephen Mogavero Now Certified as a Personal Trainer 2
... may contribute to the development or worsening of ... research abstract that will be presented Tuesday, June ... 25th Anniversary Meeting of the Associated Professional Sleep ... sleep in preschool-age children significantly predicted worse parent-reported ...
... , MONDAY, June 13 (HealthDay News) -- Spending on ... overall and especially among certain groups of patients, a new ... 18 and older who used glaucoma medication between 2001 and ... increased from $445 in 2001 to $557 in 2006. ...
... -- Patient-focused outcomes are emphasized in 10 updated performance ... that were released Monday by a trio of major ... for the use of individual practitioners and group practices ... with hypertension and those with stable coronary disease," Dr. ...
... at Case Western Reserve University School of Medicine have ... that contributes to chronic health problems. If they ... cells called macrophages, "We have a shot at a ... diabetes, heart disease and cancer," said Mukesh K. Jain, ...
... HealthDay Reporter , MONDAY, June 13 (HealthDay News) ... by up to 73 percent, especially when babies are exclusively ... considered the best food for infants, and studies have shown ... for both infants and their mothers. Now, there is more ...
... American Association for Cancer Research is pleased to announce ... families and caregivers won first place in the ... Colon and Rectal Surgeons. Separately, it received three additional ... Society of Professional Journalists. "We are honored ...
Cached Medicine News:Health News:Sleep loss in early childhood may contribute to the development of ADHD symptoms 2Health News:Medical Groups Update Heart, Blood Pressure Care Guidelines 2Health News:Medical Groups Update Heart, Blood Pressure Care Guidelines 3Health News:Genetic factor controls health-harming inflammation in obese 2Health News:Breast-feeding May Shield Against Sudden Infant Death Syndrome 2Health News:Breast-feeding May Shield Against Sudden Infant Death Syndrome 3Health News:AACR's CR magazine honored with 4 prestigious journalism awards 2
... to the National Academy of ... use of cardiac markers in ... is definitive of acute myocardial ... assay was designed for rapid ...
A fluorogenic enzyme-linked immunoassay (ELISA) for the quantitative measurement of myoglobin in human serum or plasma aiding in the diagnosis of acute myocardial infarction (AMI). Features : Dry che...
Clinical marker immunoassay kit for detection of Myoglobin....
AxSYM Myoglobin is a Microparticle Enzyme Immunoassay (MEIA) for the quantitative determination of myoglobin in human serum or plasma on the AxSYM System....
Medicine Products: